Efficacy and Safety of Kui-Yuan Chewable Tablets in Patients With Hyperuricemia

Inclusion Criteria: * Blood uric acid level\>7.0mg/dL (420 μmol/L) * The participants did not experience any acute gout attacks before treatment * The ECG of the participants was normal before treatment Exclusion Criteria: * Secondary Hyperuricemia caused by kidney disease, blood disease, or taking certain drugs, tumor radiotherapy and chemotherapy, organ transplantation, etc * Those who have used allopurinol, probenecid, benzbromarone, febuxostat or traditional Chinese medicine with uric acid lowering effect within 4 weeks before enrollment * Those who had a history of cardiovascular and cerebrovascular diseases such as stroke, TIA, MI, HF (NYHA grade II-IV), and coronary artery surgery (such as angioplasty, stent implantation, bypass grafting, etc.) * Those who had a history of gastrointestinal ulcers or gastrointestinal bleeding * Active liver disease or abnormal liver function, ALT and AST are more than 3 times the upper limit of normal * Glomerular filtration rate (eGFR)\<30mL/min/1.73m2 * Those who are allergic or intolerant to any component in Kui-Yuan chewable tablets and placebo * Those who had other autoimmune diseases * Those who are taking or need to take aspirin, other salicylic acids, heparin, Dicoumarol and other anticoagulants and antiplatelet aggregation drugs * Those who taking Diuretic * Those who had a history of alcohol or drug dependence, or those who require long-term daily use of painkillers for any reason * Pregnancy, lactation, or planned pregnancy within 3 months after the last study medication